Colorectal Cancer Clinical Trial
Official title:
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma
The purpose of this research study to find out if the drug trametinib in combination with ruxolitinib is safe, tolerable and has beneficial effects in people who has certain type of cancers including the type that you have. Patients with RAS mutant colorectal cancer and pancreatic adenocarcinoma are invited to participate in this study. This is the first time that both trametinib and ruxolitinib are studied in combination. Trametinib is marketed in several countries with the brand name Mekinist® for the treatment of melanoma (a type of skin cancer). Trametinib has been studied extensively in cancer and has been tested in many patients. Ruxolitinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases and is approved for treatment of adult polycythemia vera and myelofibrosis. Ruxolitinib has been studied extensively in many patients.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | March 31, 2024 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Patients (male or female) = 21. - Patients with histological diagnosis of RAS mutant advanced colorectal and pancreatic adenocarcinoma having received at least 1 prior line of systemic therapy. Pancreatic cancer patients with KRAS mutation detected on plasma profiling having received at least 1 prior line of systemic therapy. - Patients must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1. - Life expectancy of at least 3 months. - Written informed consent that is consistent with ICH-GCP guidelines. - Eastern Cooperative Oncology Group (ECOG) performance score = 2. - Have adequate organ and hematologic function, as determined by: - Absolute neutrophil count (ANC) = 1,500/µl. - Platelets = 100,000/µl. - Haemoglobin = 9g/dL. - Aspartate Amino Transferase (AST)/ Alanine Amino Transferase (ALT) = 2.5 x upper limit of normal (ULN = 5 x ULN is acceptable if liver metastases are present). - Total bilirubin =1.5 x ULN (< 3 ULN for patients with Gilbert syndrome). - Creatinine clearance = 60ml/min. - Prothrombin time and activated partial thromboplastin time = 1.5 x upper limit of normal (ULN) per institutional laboratory normal range. - Ejection fraction = 50% with no symptoms attributable to heart failure. - Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of =450 ms in males or =470 ms in females. - For female patients of childbearing potential, a negative pregnancy test must be documented prior to enrolment. - Female and male patients who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation. - Have the willingness and ability to comply with scheduled visits and study procedures. Exclusion Criteria: - Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days of study drug commencement, or 5 half-lives, whichever is shorter, and with recovery of clinically significant toxicities from that therapy. - Received monoclonal antibodies or had surgery within 30 days of the first dose of study drug. - Have been diagnosed with another primary malignancy within the past 3 years of study drug commencement (except for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate cancer). - Have CNS metastases that are symptomatic, neurologically unstable, or requiring an increasing dose of corticosteroids. - Have meningeal involvement or spinal cord compression. - Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: - Myocardial infarction (MI) within 6 months prior to the first dose. - Unstable angina within 6 months prior to first dose. - History of congestive heart failure (CHF). - History of clinically significant atrial arrhythmia. - Any history of ventricular arrhythmia. - Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose. - Have history or the presence of pulmonary interstitial disease or drug related pneumonitis. - Have an ongoing or active infection. - Patients with active HBV and HCV are excluded unless they are undergoing treatment for HBV and HCV. - Have a history of or active significant gastrointestinal (GI) bleeding within 3 months of the first dose. - Patients who are on immunosuppressive therapy. - Patients who have retinal vein occlusion and retinal pigment epithelial detachment. - On medications which are potent and moderate inhibitor and inducers of CYP3A4. - Patients with moderate to severe hepatic impairment (Child Pugh B and C). - Patients with history of severe allergic skin reactions or current skin conditions. |
Country | Name | City | State |
---|---|---|---|
Singapore | National Cancer Centre | Singapore |
Lead Sponsor | Collaborator |
---|---|
National Cancer Centre, Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose | Highest dose level at which less than one-third of the patients in the dose level experienced dose limiting toxicities (DLTs) during the first cycle of treatment | 28 days (1 cycle) | |
Secondary | Frequency and severity of treatment-emergent Adverse Events and Serious Adverse Events | To assess the safety of the drug combination. During the dose escalation phase, this includes the incidences of dose limiting toxicities during the first 2 cycles of treatment. | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline hematology laboratory parameters during treatment - Haemoglobin | Unit of measure: g/dL. To assess the safety of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline hematology laboratory parameters during treatment - White blood count, Platelets, Absolute neutrophil count | Unit of measure: x 10^9/L. To assess the safety of the drug combination. | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline hematology laboratory parameters during treatment - Neutrophils | Unit of measure: Percentage component of white blood cells. To assess the safety of the drug combination. | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Urea, Sodium, Potassium, Chloride, Bicarbonate, Glucose, Magnesium, Calcium, Phosphate, Total cholesterol, High and low density lipoprotein, Triglycerides | Unit of measure: mmol/L. To assess the safety of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Uric acid, Creatinine, Total bilirubin | Unit of measure: umol/L. To assess the safety of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Total protein, Albumin | Unit of measure: g/L. To assess the safety of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Alkaline phosphatase, Alanine transaminase, Aspartate transaminase, Lactate dehydrogenase, Beta-human chorionic gonadotrophin | Unit of measure: U/L. To assess the safety of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Frequency of dose interruptions | To assess the tolerability of the drug combination. | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Frequency of dose reductions | To assess the tolerability of the drug combination | From time of first study drug administration until 30 days after last dose of study drug | |
Secondary | Pharmacokinetics (PK): Trough concentrations of trametinb | Trough concentrations of trametinb at different cycles of combination treatment with ruxolitinib | From cycle 1-6 of study (each cycle is 28 days) | |
Secondary | Tumour Markers: CEA and CA 19-9 in blood samples | Changes from baseline tumour markers (CEA and CA 19-9) in blood samples | From cycle 1 up to last cycle of treatment (each cycle is 28 days) | |
Secondary | Overall Response Rate | The best overall response is the best response recorded from the start of the treatment until disease progression (PD)/ recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). | From time of first study drug administration until first occurrence of disease progression, up to 2 years | |
Secondary | Disease Control Rate | Percentage of patients who have achieved complete response, partial response and stable disease in accordance to RECIST 1.1. | From time of first study drug administration until best overall response, first occurence of disease progression, up to 2 years | |
Secondary | Progression Free Survival | Time elapsed between treatment initiation and tumour progression or death from any cause, with censoring of patients who are lost to follow-up. | From time of first study drug administration until first occurence of disease progression, or death from any cause, up to 2 years | |
Secondary | Overall Survival | Time elapsed between treatment initiation and death from any cause, with censoring of patients who are lost to follow-up. | From time of first study drug administration to death from any cause, up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |